Detection of amyloid growth is commonly carried out by measurement of solution turbidity, a low-cost assay procedure based on the intrinsic light scattering properties of the protein aggregate. Here, we review the biophysical chemistry associated with the turbidimetric assay methodology, exploring the reviewed literature using a series of pedagogical kinetic simulations. In turn, these simulations are used to interrogate the literature concerned with in vitro drug screening and the assessment of amyloid aggregation mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135725 | PMC |
| http://dx.doi.org/10.1007/s12551-016-0233-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-neuroinflammatory and Neuroprotective Effects of T-006 on Alzheimer's Disease Models by Modulating TLR4-Mediated MyD88/ NF-κB Signaling.
CNS Neurol Disord Drug Targets
January 2025
School of Medicine, Foshan University, Foshan, 528000, China.
Introduction: Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau expression and phosphorylation in AD transgenic mouse models. Recently, T-006 has been proven to dramatically decrease the levels of total Amyloid β (Aβ) peptide and Glial Fibrillary Acidic Protein (GFAP) and suppress the expression of ionized calcium binding adaptor molecule-1 (Iba-1) in APP/PS1 mice.
View Article and Find Full Text PDFRelationship Between Maternal Serum Amyloid A Levels and Neonatal Outcomes in Preterm Births.
Cureus
December 2024
Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, ROU.
This study investigated the relationship between maternal serum amyloid A (SAA) levels, a biomarker of systemic inflammation, and specific neonatal outcomes in preterm birth (PTB). The study included 66 consecutive pregnant women hospitalized for spontaneous preterm delivery (ranging from 28 to 36 gestational weeks), at the Timisoara Municipal Hospital. The study measured mSAA levels to assess their potential as predictors of fetal outcomes (respiratory distress syndrome [RDS]), as well as their association with APGAR score, neonatal leukocyte count, and C-reactive protein (CRP) levels as indicators of neonatal status and response.
View Article and Find Full Text PDFAnalysis of Levels of Vitamin D, Beta-Amyloid 42, Indoxyl Sulfate, and Serum Parathyroid Hormone in Hemodialysis Patients with Cognitive Impairment.
Innov Clin Neurosci
December 2024
Prof. Syafrita and Drs. Susanti and Indra are with the Department of Neurology, Faculty of Medicine at Andalas University in Padang, Indonesia.
Objective: Cognitive impairment is a recurrent complication in people with chronic kidney disease (CKD), which includes those undergoing hemodialysis (HD). Researchers aimed to analyze vitamin D levels, beta-amyloid 42, indoxyl sulfate, and serum parathyroid hormone (PTH) in patients with cognitive impairment who underwent HD.
Design: This comparative, cross-sectional study was conducted at the HD unit of Dr.
Patient stratification by genetic risk in Alzheimer's disease is only effective in the presence of phenotypic heterogeneity.
PLoS One
January 2025
Washington University School of Medicine, NeuroGenomics and Informatics Center, St. Louis, MO, United States of America.
Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer's disease (AD), where longitudinal cohorts measure disease "progression," defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science.
View Article and Find Full Text PDFBehavioral Reaction to Amyloid β Status Disclosure Among Research Participants with High‐AD Risk in Israel.
Alzheimers Dement
December 2024
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel
Background: Amyloid beta (Aβ) deposition marks an early stage in the progression of Alzheimer's disease (AD), detectable in‐vivo years before symptoms emerge and targeted by recently FDA‐approved drugs. This has propelled advancements in understanding, measuring, and treating AD, paving the way for disease prevention in those at risk. However, the psychological impact of disclosing Aβ status to cognitively unimpaired individuals remains underexplored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!